翰森制药(03692)建议发行46.8亿港元于2033年到期的零息可换股债

Core Viewpoint - Hansoh Pharmaceutical (03692) has announced a subscription agreement with an underwriter, allowing the company to issue convertible bonds, which can be converted into shares at a specified price, potentially raising significant capital [1] Group 1: Subscription Agreement Details - The company has conditionally agreed to issue bonds to the underwriter, who will subscribe individually rather than collectively, subject to the terms of the agreement [1] - The bonds can be converted into shares at an initial conversion price of HKD 57.39 per share, potentially resulting in the issuance of approximately 81.55 million shares, representing about 1.35% of the company's existing share capital as of the announcement date [1] - The net proceeds from the bond issuance are expected to be approximately HKD 4.64 billion, with a net issue price of about HKD 56.90 per share based on the initial conversion price [1] Group 2: Listing and Trading - The company plans to apply for the listing and trading of the bonds on the Vienna MTF operated by the Vienna Stock Exchange [1] - Additionally, the company will seek approval for the listing and trading of the converted shares on the Hong Kong Stock Exchange [1]